FPWR Invests in Aardvark, Gut-targeting PWS Therapy ARD-101

FPWR Invests in Aardvark, Gut-targeting PWS Therapy ARD-101

297780

FPWR Invests in Aardvark, Gut-targeting PWS Therapy ARD-101

The Foundation for Prader-Willi Research (FPWR) announced its support for ARD-101, an investigational, gut-targeting Prader-Willi syndrome (PWS) therapy, by investing in Aardvark Therapeutics, the treatment’s developer. “FPWR is committed to advancing the development of innovative treatments through multiple channels,” John Walter, CEO of FPWR, said in a press release. “Aardvark’s drug targets multiple pathways in the gut potentially relevant to PWS and we look forward to confirming the benefits this potential therapeutic may have for…

You must be logged in to read/download the full post.